Asset Details
Do you wish to reserve the book?
Retrospective Analysis of the Efficacy of Gemcitabine for Previously Treated AIDS-Associated Kaposi’s Sarcoma in Western Kenya
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Retrospective Analysis of the Efficacy of Gemcitabine for Previously Treated AIDS-Associated Kaposi’s Sarcoma in Western Kenya
Do you wish to request the book?
Retrospective Analysis of the Efficacy of Gemcitabine for Previously Treated AIDS-Associated Kaposi’s Sarcoma in Western Kenya
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Retrospective Analysis of the Efficacy of Gemcitabine for Previously Treated AIDS-Associated Kaposi’s Sarcoma in Western Kenya
2010
Overview
Objectives: Evaluation of outcomes in the use of single-agent gemcitabine for the treatment of AIDS-associated Kaposi’s sarcoma (KS) in a western Kenyan cancer treatment program. Methods: Retrospective chart review of all patients with KS treated with single agent gemcitabine following failure of first-line Adriamycin, bleomycin, and vincristine (ABV). Baseline demographics were collected, and clinicians’ assessments of response were utilized to fill out objective criteria for both response as well as symptom benefit assessment. Results: Twenty-three patients with KS who had previously failed first-line therapy with ABV were evaluated. Following treatment, 22 of the 23 patients responded positively to treatment with stable disease or better. Of the 18 patients who had completed therapy, with a median follow-up of 5 months, 12 patients had no documented progression. Conclusions: Treatment options in the resource-constrained setting are limited, both by financial constraints as well as the need to avoid myelotoxicity, which is associated with high morbidity in this treatment setting. This work shows that gemcitabine has promising activity in KS, with both objective responses and clinical benefit observed in this care setting. Gemcitabine as a single agent merits further investigation for AIDS-associated KS.
Publisher
Karger,S. Karger AG
Subject
Acquired immune deficiency syndrome
/ Acquired Immunodeficiency Syndrome - complications
/ Adult
/ AIDS
/ Antimetabolites, Antineoplastic - therapeutic use
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Biological and medical sciences
/ Cancer
/ Deoxycytidine - analogs & derivatives
/ Deoxycytidine - therapeutic use
/ Doxorubicin - therapeutic use
/ Female
/ Humans
/ Kenya
/ Male
/ Reducing the Worldwide Burden of Cancer
/ Sarcoma, Kaposi - drug therapy
/ Tumors
